Mostrando 5 resultados de: 5
Filtros aplicados
Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusNimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
ArticleAbstract: EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis.Palabras claves:brief research report nimotuzumab, covid-19, eGFR, FIBROSIS, inflammation, Monoclonal antibody, SARS-COV-2Autores:Batista D., Cabrera L., Diaz H., Domeq M., Gorte A., Hernández A., Hernández R., Jiménez J., Jova J.H., Luaces P.L.o., Martínez A., Medel L., Pérez Ruiz L., Porto L., Ramos M., Saavedra Hernández D., Sánchez L., Tania Crombet, Travieso N., Troche M., Valdés L., Valls A.R.Fuentes:scopusPlacebo response in depression. Results from a clinical trial in Cuba
ReviewAbstract: Some aspects related with depression and the use of placebo in clinical trials were reviewed considePalabras claves:antidepressants, Clinical trial, Depression, PlaceboAutores:Alonso Rodríguez C.A., Anido Guzmán B.M., Areces Hernández R., Argüelles Mederos T.E., Ballagas Flores C., Barroso Pacheco L., Betancourt Reyes L.M., Bolaños Díaz B., Caballero Hernandez M., Cachimaille Benavides Y., Campos Zamora M., Caraballo Pons I., Colás Onofre C., Cordero Jiménez J.R., De La Parte Pérez L.A., Despaigne Campos T., Díaz Rodríguez O., Echevarría Feijoo S., Espinosa Herbella M., Espinosa Rodríguez N.B., Fernández Díaz N., Fernández Lopez O.I., Gallardo Alvarez M., García Arbola B., García Menéndez R., González Hidalgo T., Guerrero Nicado M.C., Hernández Castro V.H., Hernández Reyes V., Hydes Thomas E.B., Jiménez Rivero G., Jústiz Lugo J., Leyva Concepción M., Llanes Iglesias M., Llinás Carrillo S., Lomba Acevedo P., López Pedroso M.J., Martha M. Fors-López, Martín Castillo M.S., Martín Pena M.E., Martínez Hurtado A.M., Martínez Mujica B., Mata Rodríguez J.L., Mayor González L., Mendoza Rodríguez Y., Naranjo Alvarez S., Padrón Hechavarría A., Pascual López M.A., Peña Galván L.Y., Pérez López M., Pérez Pérez A., Pérez Ruiz L., Prado Sosa O., Pulido Valdés M.D., Quintana Esquivel B., Ramos Cedeño A., Robaina M., Rodríguez Feria Z., Roque Cancio D., Ruiz Estrada R., Soto Argüelles G., Sotolongo García Y., Suárez Caballero A., Talavera Núñez M.D.C., Teope Romero S.C., Toledo Jiménez E., Trutié Rodríguez L., Urrutia Zerquera E., Valdevila Figueira A., Valerio Mendiondo A.J., Valle Cabrera R., Valls Hung A.R., Veranes Marcelín N., Zarragoitía Alonso I.Fuentes:scopusSafety of racotumomab in the treatment of patients with non-small cell lung cancer
ArticleAbstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary toPalabras claves:Adverse events, Clinical trial, Non-small cell lung cancer, RacotumomabAutores:Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.Fuentes:scopusSecurity 1E10 anti-idiotypic vaccine in patients with tumors of different locations
ArticleAbstract: Cancer is a leading cause of death in Cuba and the world. Lung cancer is the leading cause of death,Palabras claves:Anti-idiotypic, Breast, Cáncer, COLON, Non-small cell lung vaccine, security, Small cell lungAutores:Alfonso S., Carmen Elena Viada, García E., Guerra P.P., Hernández M., Macías A.E., MARTHA FORS, Martha M. Fors-López, Mendoza I.C., Neninger Vinageras E., Pérez Ruiz L., Santiesteban E.R., Vázquez A.M.Fuentes:googlescopus